Genomic surveillance of invasive Streptococcus pneumoniae strains in south Tunisia during 2012–2022
Microbial Genomics · 2025
DOI: 10.1099/mgen.0.001448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Genomics, 2025. Verfasst von Fahmi Smaoui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory Microorganisms and Human Disease "MPH LR03SP03", Laboratory of Microbiology, Habib Bourguiba University Hospital, Sfax, Tunisia. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Purpose
Invasive pneumococcal disease (IPD) remains a major global public health concern due to its high morbidity and mortality rates, particularly among children and the elderly. This study aimed to apply whole-genome sequencing (WGS) to characterize Streptococcus pneumoniae strains responsible for IPD in south Tunisia, including serotype distribution, clonal relationship and antimicrobial resistance (AMR) profiles.
Methods
A total of 148 IPD S. pneumoniae isolates were collected from the microbiology laboratory at Habib Bourguiba University Hospital in Sfax, Tunisia, between 2012 and 2022. These isolates underwent WGS using Illumina technology. Bioinformatic analyses were performed to determine serotype distribution, sequence types (STs), Global Pneumococcal Sequence Clusters (GPSCs), phylogenetic relationships and AMR determinants.
Results
Twenty-six different serotypes were identified, with the most prevalent being 14 (18%), 3 (13%), 19A (12%) and 19F (11%). The isolates showed high genomic diversity, as they belonged to 32 GPSCs and 59 STs. The most common GPSCs were GPSC-6, GPSC-10 and GPSC-44, associated with serotypes 14, 19A and 19F, respectively. The most frequent STs were ST2918, ST179 and ST3772. The most common resistance genes were erm B (53%) and tet M (55%), which were linked to resistance against erythromycin and tetracycline, respectively. There was a considerable concordance between WGS-based and phenotypic resistance profiles for most tested antibiotics, with few major and very major errors for most antibiotics. Temporal analysis showed a decline in serotypes 19F and 9V throughout the study period, which was associated with slight decreases in GPSC-6 and GPSC-44, while serotype 19A and GPSC-10 sharply increased.
Conclusion
This study highlights the substantial genomic diversity, serotype distribution and high prevalence of AMR among IPD S. pneumoniae isolates in south Tunisia, underscoring the need for continued surveillance and effective vaccination strategies to combat this persistent public health threat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Laboratory Microorganisms and Human Disease "MPH LR03SP03", Laboratory of Microbiology, Habib Bourguiba University Hospital, Sfax, Tunisia.
- Laboratory of Microbiology, Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia.
Förderung
- Pfizer
Zitieren
APA
Smaoui, F., Ksibi, B., Ben Ayed, N., Ktari, S., Gargouri, O., Mezghani, S., Mnif, B., Mahjoubi, F., Karray, H., & Hammami, A. (2025). Genomic surveillance of invasive Streptococcus pneumoniae strains in south Tunisia during 2012–2022. Microbial Genomics. https://doi.org/10.1099/mgen.0.001448
Vancouver
Smaoui F, Ksibi B, Ben Ayed N, Ktari S, Gargouri O, Mezghani S, et al. Genomic surveillance of invasive Streptococcus pneumoniae strains in south Tunisia during 2012–2022. Microbial Genomics. 2025. doi:10.1099/mgen.0.001448
BibTeX
@article{Smaoui2025,
author = {Smaoui, Fahmi and Ksibi, Boutheina and Ben Ayed, NourElhouda and Ktari, Sonia and Gargouri, Omar and Mezghani, Senda and Mnif, Basma and Mahjoubi, Faouzia and Karray, Héla and Hammami, Adnene},
title = {Genomic surveillance of invasive Streptococcus pneumoniae strains in south Tunisia during 2012–2022},
journal = {Microbial Genomics},
year = {2025},
doi = {10.1099/mgen.0.001448}
}
EUVIMED